SN 13,274

Malaria plagues nearly half the world's population. Since the war, researchers have been inching closer to a definitive cure for the disease. Last week it looked as if they just about had it--a new drug which, used with quinine, permanently cures 95% of all relapsing malaria cases. Still unnamed, it is identified as SN 13,274. The drug was developed at Columbia University, with U.S. Public Health Service aid, by a group of chemists headed by Dr. Robert C. Elderfield.

Relapsing malaria is difficult to cure because the tiny parasites that cause the disease lurk in the viscera, where they are hard to reach with drugs. SN 13,274 is the best of a long series of drugs that researchers have developed as improvements on quinine and atabrine. Dr. Elderfield hopes that supplies of the drug will soon be available for nearly half a million ex-G.I.s who have had relapses of malaria.

This file is automatically generated by a robot program, so reader's discretion is required.